This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Hygromycin B
DrugBank Accession Number
DB11520
Background

Hygromycin B is an aminoglycoside antibiotic produced by the bacterium Streptomyces hygroscopicus which kills bacteria, fungi and higher eukaryotic cells by inhibiting protein synthesis.

Type
Small Molecule
Groups
Vet approved
Structure
Weight
Average: 527.524
Monoisotopic: 527.232638263
Chemical Formula
C20H37N3O13
Synonyms
Not Available

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirHygromycin B may decrease the excretion rate of Abacavir which could result in a higher serum level.
AceclofenacThe risk or severity of nephrotoxicity can be increased when Aceclofenac is combined with Hygromycin B.
AcemetacinThe risk or severity of nephrotoxicity can be increased when Hygromycin B is combined with Acemetacin.
AcenocoumarolThe risk or severity of bleeding can be increased when Hygromycin B is combined with Acenocoumarol.
AcetaminophenHygromycin B may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
AcetylcholineThe therapeutic efficacy of Acetylcholine can be decreased when used in combination with Hygromycin B.
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Hygromycin B is combined with Acetyldigitoxin.
Acetylsalicylic acidThe risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Hygromycin B.
AclidiniumHygromycin B may decrease the excretion rate of Aclidinium which could result in a higher serum level.
AcrivastineHygromycin B may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
3XQ2233B0B
CAS number
31282-04-9
InChI Key
GRRNUXAQVGOGFE-HUCHGKBZSA-N
InChI
InChI=1S/C20H37N3O13/c1-23-7-2-5(21)9(26)15(10(7)27)33-19-17-16(11(28)8(4-25)32-19)35-20(36-17)18(31)13(30)12(29)14(34-20)6(22)3-24/h5-19,23-31H,2-4,21-22H2,1H3/t5-,6+,7+,8-,9+,10-,11+,12-,13+,14-,15-,16+,17+,18-,19+,20?/m1/s1
IUPAC Name
(3'R,3aS,4S,4'S,5'R,6R,6'R,7S,7aS)-4-{[(1R,2S,3R,5S,6R)-3-amino-2,6-dihydroxy-5-(methylamino)cyclohexyl]oxy}-6'-[(1S)-1-amino-2-hydroxyethyl]-6-(hydroxymethyl)-tetrahydro-3aH-spiro[[1,3]dioxolo[4,5-c]pyran-2,2'-oxane]-3',4',5',7-tetrol
SMILES
[H][C@@]12OC3(O[C@]1([H])[C@H](O[C@]1([H])[C@@H](O)[C@H](N)C[C@H](NC)[C@H]1O)O[C@H](CO)[C@@H]2O)O[C@]([H])([C@@H](N)CO)[C@H](O)[C@H](O)[C@H]3O

References

General References
  1. Watson AD, Burnett DC: Hygromycin B and deaf dogs. Aust Vet J. 1989 Sep;66(9):302-3. [Article]
  2. Davidson I, Hebert CN: The international reference preparation of hygromycin B. Bull World Health Organ. 1966;35(6):933-43. [Article]
  3. Tsyganov VA, Pronina MI: [Selection of strains producing hygromycin B using roentgen rays]. Antibiotiki. 1970 Aug;15(8):679-82. [Article]
  4. Begue WJ, Kline RM: Semiquantitative microbiological residue method for hygromycin B in chicken eggs. J Assoc Off Anal Chem. 1973 Jan;56(1):20-2. [Article]
  5. Radman I, Greiss S, Chin JW: Efficient and rapid C. elegans transgenesis by bombardment and hygromycin B selection. PLoS One. 2013 Oct 9;8(10):e76019. doi: 10.1371/journal.pone.0076019. eCollection 2013. [Article]
  6. KELLEY GW, OLSEN LS: Critical tests of hygromycin B as an ascaricide of swine. Cornell Vet. 1960 Jan;50:60-5. [Article]
  7. Gonzalez R, Ferrer S, Buesa J, Ramon D: Transformation of the dermatophyte Trichophyton mentagrophytes to hygromycin B resistance. Infect Immun. 1989 Sep;57(9):2923-5. [Article]
  8. Makridou P, Burnett C, Landy T, Howard K: Hygromycin B-selected cell lines from GAL4-regulated pUAST constructs. Genesis. 2003 Jun;36(2):83-7. [Article]
  9. Zhuo Q, Yang X: [Methods of hygromycin B phosphotransferase activity assay in transgenic plant]. Wei Sheng Yan Jiu. 2004 Jul;33(4):502-4. [Article]
  10. Gatti PJ, Choi B, Haislip AM, Fermin CD, Garry RF: Inhibition of HIV type 1 production by hygromycin B. AIDS Res Hum Retroviruses. 1998 Jul 1;14(10):885-92. [Article]
ChemSpider
28634700
RxNav
1426887
Wikipedia
Hygromycin_B

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility213.0 mg/mLALOGPS
logP-2.9ALOGPS
logP-6.4ChemAxon
logS-0.39ALOGPS
pKa (Strongest Acidic)11.41ChemAxon
pKa (Strongest Basic)9.55ChemAxon
Physiological Charge3ChemAxon
Hydrogen Acceptor Count16ChemAxon
Hydrogen Donor Count11ChemAxon
Polar Surface Area272.06 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity114.05 m3·mol-1ChemAxon
Polarizability50.66 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at February 26, 2016 17:32 / Updated at November 06, 2020 02:38